首页|以肠道菌群为辅助的结直肠癌免疫治疗进展及未来展望

以肠道菌群为辅助的结直肠癌免疫治疗进展及未来展望

扫码查看
结直肠癌(colorectal cancer,CRC)是世界范围内的高发病、高死亡疾病,其病因多且交错.多研究证实,结直肠肿瘤免疫疗法的效果和并发症与特定肠道微生物群的组成有关,调节这部分菌群的辅助治疗有望促进CRC免疫治疗效果最大化.本文就总结肠道菌群作用在CRC免疫治疗中的科学证据,重点是特定菌群及菌群调节相关治疗方案在CRC免疫治疗中的现状作一概述.
Progress and future prospects of immunotherapy for colorectal cancer assisted by gut flora
Colorectal cancer(CRC)is a disease with high morbidity and high mortality worldwide,and its etiology is multiple and intertwined.Multiple studies have confirmed that the effects and complications of colorectal tumor immuno-therapy are related to the composition of specific gut microbiota,and adjuvant therapy that modulates this part of the mi-crobiota is expected to maximize the effect of CRC immunotherapy.We summarized the scientific evidence for the role of gut microbiota in CRC immunotherapy,focusing on the current status of specific microbiota and microbiota modulation-related treatment regimens in CRC immunotherapy.

Gut floraColorectal cancerImmunosuppressantsPrecision medicineTraditional Chinese medicine

归明彬、王雅楠、邹敏、高华、高峰

展开 >

中国人民解放军联勤保障部队第九四○医院结直肠肛门外科,甘肃 兰州 730050

肠道菌群 结直肠癌 免疫抑制剂 精准医疗 中医药

2024

胃肠病学和肝病学杂志
郑州大学

胃肠病学和肝病学杂志

CSTPCD
影响因子:1.029
ISSN:1006-5709
年,卷(期):2024.33(12)